Subtopic Deep Dive

Non-Histone Protein Arginine Methylation in Signaling
Research Guide

What is Non-Histone Protein Arginine Methylation in Signaling?

Non-Histone Protein Arginine Methylation in Signaling refers to PRMT-mediated arginine methylation of non-histone proteins like signaling kinases and splice factors that modulates oncogenic pathways such as MAPK and PI3K in cancer.

PRMTs catalyze symmetric and asymmetric arginine methylation on substrates including RAF, AKT, and splicing regulators. This PTM alters protein interactions and signaling cascades driving cancer proliferation. Over 20 papers document PRMT inhibitors targeting these modifications (Hwang et al., 2021, 234 citations).

Curated Papers

Key Challenges

Why It Matters

Arginine methylation of non-histone targets like MAP3K2 by SMYD3 activates Ras-driven lung cancer via enhanced MAPK signaling (Mazur et al., 2014, 404 citations). PRMT deregulation promotes therapy resistance in solid tumors through PI3K/AKT pathway hyperactivity (Hwang et al., 2021). GSK-3 phosphorylation intersects with PRMT-modified signaling hubs, offering dual-targeting opportunities in hepatocellular carcinoma (McCubrey et al., 2014, 484 citations).

Key Research Challenges

Identifying Novel Substrates

Proteomics screens reveal few non-histone arginine methylation sites amid lysine modifications. Distinguishing symmetric from asymmetric methylation requires MS/MS validation. Few studies map PRMT1/5 specificity in cancer signaling (Hwang et al., 2021).

Linking Methylation to Pathways

Methylation effects on RAF/AKT stability remain unquantified in vivo. MAPK/PI3K crosstalk confounds PRMT inhibitor phenotypes. ERK1/2 hyperactivation models overlook arginine-specific roles (Wagner et al., 2013, 193 citations).

Developing Selective Inhibitors

PRMT5 inhibitors show off-target histone effects limiting clinical translation. Non-histone signaling requires substrate-mimetic probes. GSK-3/PRMT dual modulation lacks structural data (McCubrey et al., 2014).

Essential Papers

The role of m6A RNA methylation in cancer metabolism

Yuanyuan An, Hua Duan · 2022 · Molecular Cancer · 771 citations

GSK-3 as potential target for therapeutic intervention in cancer

James A. McCubrey, Linda S. Steelman, Fred E. Bertrand et al. · 2014 · Oncotarget · 484 citations

The serine/threonine kinase glycogen synthase kinase-3 (GSK-3) was initially identified and studied in the regulation of glycogen synthesis. GSK-3 functions in a wide range of cellular processes. A...

SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer

Paweł K. Mazur, Nicolas Reynoird, Purvesh Khatri et al. · 2014 · Nature · 404 citations

p21 in Cancer Research

Bahar Shamloo, Sinem Usluer · 2019 · Cancers · 337 citations

p21 functions as a cell cycle inhibitor and anti-proliferative effector in normal cells, and is dysregulated in some cancers. Earlier observations on p21 knockout models emphasized the role of this...

Protein arginine methyltransferases: promising targets for cancer therapy

Jee Won Hwang, Yena Cho, Gyu‐Un Bae et al. · 2021 · Experimental & Molecular Medicine · 234 citations

Abstract Protein methylation, a post-translational modification (PTM), is observed in a wide variety of cell types from prokaryotes to eukaryotes. With recent and rapid advancements in epigenetic r...

Role of m6A writers, erasers and readers in cancer

Zhen Fang, Wentong Mei, Chang Qu et al. · 2022 · Experimental Hematology and Oncology · 226 citations

Mechanisms of transcriptional repression by histone lysine methylation

Philip Hublitz, Mareike Albert, Antoine Hfmpeters et al. · 2009 · The International Journal of Developmental Biology · 202 citations

During development, covalent modification of both, histones and DNA contribute to the specification and maintenance of cell identity. Repressive modifications are thought to stabilize cell type spe...

Reading Guide

Foundational Papers

Read McCubrey et al. (2014, 484 citations) first for GSK-3 signaling overview intersecting PRMT paths, then Mazur et al. (2014, 404 citations) for SMYD3-MAP3K2 prototype substrate.

Recent Advances

Study Hwang et al. (2021, 234 citations) for PRMT therapeutic targets and Wagner et al. (2013, 193 citations) for ERK/PRMT epigenetics.

Core Methods

Proteomics (IP-MS/MS), inhibitors (GSK343 for PRMT5), signaling assays (Ras-Glo, phospho-ELISA), CRISPR validation.

How PapersFlow Helps You Research Non-Histone Protein Arginine Methylation in Signaling

Discover & Search

Research Agent uses searchPapers('PRMT5 non-histone substrates cancer signaling') to retrieve Hwang et al. (2021), then citationGraph reveals 234 citing papers on MAPK links, and findSimilarPapers expands to Mazur et al. (2014) SMYD3-MAP3K2 substrate.

Analyze & Verify

Analysis Agent applies readPaperContent on Mazur et al. (2014) to extract MAP3K2 methylation assays, verifyResponse with CoVe cross-checks Ras activation claims against McCubrey et al. (2014) GSK-3 data, and runPythonAnalysis parses proteomics tables for substrate motifs using pandas.

Synthesize & Write

Synthesis Agent detects gaps in PRMT-non-histone signaling via contradiction flagging between Hwang et al. (2021) and Wagner et al. (2013), Writing Agent uses latexEditText for pathway diagrams, latexSyncCitations integrates 20+ refs, and latexCompile generates review figures with exportMermaid for MAPK/PI3K networks.

Use Cases

"Analyze PRMT5 methylation sites from proteomics data in lung cancer papers"

Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas motif extraction, matplotlib site frequency plots) → researcher gets quantified substrate consensus sequences.

"Write LaTeX review on PRMT inhibitors targeting RAF signaling"

Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (Hwang 2021, Mazur 2014) + latexCompile → researcher gets camera-ready section with 15 citations.

"Find code for modeling arginine methylation kinase assays"

Research Agent → paperExtractUrls (McCubrey 2014) → paperFindGithubRepo → githubRepoInspect → researcher gets simulation scripts for GSK-3/PRMT crosstalk.

Automated Workflows

Deep Research workflow runs searchPapers on 'non-histone PRMT cancer' → citationGraph → DeepScan 7-step verification → structured report ranking 50+ papers by substrate evidence. Theorizer generates hypotheses linking PRMT5 to GSK-3 via methylation-phosphorylation competition (McCubrey et al., 2014). DeepScan checkpoints verify Mazur et al. (2014) claims against 2009 histone methylation baselines.

Try Doxa for Non-Histone Protein Arginine Methylation in Signaling Research

Frequently Asked Questions

What defines non-histone protein arginine methylation in signaling?

PRMT1-9 enzymes add MMA, SDMA, aMMA to arginine residues on signaling proteins like RAF, AKT, MAP3K2, altering kinase activity and pathway flux in cancer.

What methods identify these modifications?

IP-MS proteomics with PRMT inhibitors, nanoLC-MS/MS for mono/di-methylarginine, and CRISPR PRMT knockouts quantify signaling impacts (Hwang et al., 2021).

What are key papers?

Hwang et al. (2021) reviews PRMT therapy (234 citations); Mazur et al. (2014) links SMYD3-MAP3K2 methylation to Ras cancer (404 citations); McCubrey et al. (2014) details GSK-3 signaling intersections (484 citations).